Certified by Founder
Lodge
Initial Therapeutics
start up
United States
- South San Francisco, California
- 02/05/2023
- Series A
- $75,000,000
Initial Therapeutics is discovering and developing a new class of small-molecule medicines designed to halt pathogenic protein formation in the earliest stages.
Initial’s approach is unique and starkly differentiated from protein degradation and other interventions that recognize and tackle proteins only after they have been fully formed.
- Industry Biotechnology Research
- Website https://initialtx.com/
- LinkedIn https://www.linkedin.com/company/initial-therapeutics/people/
Ciphero | $2,500,000 | (Dec 23, 2025)
beycome | $2,500,000 | (Dec 23, 2025)
Givefront | $2,000,000 | (Dec 23, 2025)
StretchSense | $2,300,000 | (Dec 23, 2025)
ZeroPhase | $6,800,000 | (Dec 23, 2025)
Peripheral Labs | $3,600,000 | (Dec 23, 2025)
Ethereal Exploration Guild | $21,000,000 | (Dec 23, 2025)
LatentForce | $1,700,000 | (Dec 23, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Amphix Bio | $12,500,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)